Farooq Ali Khan

Farooq Ali Khan

Auto-generated profile, based on publicly available information

Farooq Ali Khan

Sri Indu Institute of Pharmacy, Hyderabad, India

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
YSYuvraj Singh
Yuvraj Singh
JMJaya Gopal Meher
Jaya Gopal Meher
KRKavit Raval
Kavit Raval
FKFarooq Ali Khan
Farooq Ali Khan
MCMohini Chaurasia
Mohini Chaurasia
MKManish K. Kedar
Manish K. Kedar

20 March 2019 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
FKFarooq Ali Khan
Farooq Ali Khan
KNKaushik Narasimhan
Kaushik Narasimhan
CSC.S.V. Swathi
C.S.V. Swathi
SMSayyad Mustak
Sayyad Mustak
GMGulam Mustafa
Gulam Mustafa
SASohail Akhter
Sohail Akhter
Background: 3D printing/Additive Manufacturing seems a pragmatic approach to realize the quest for a truly customized and personalized drug delivery. 3DP technology, with innovations in pharmaceutical development and an interdisciplinary approach to finding newer Drug Delivery Systems can usher a new era of treatments to various diseases. The true potential of this is yet to be realized, and the US-FDA is focusing on the regulatory science of 3D printed medical devices to help patients access this technology safely and effectively. The approval of the first 3D printed prescription medicine by FDA is a promising step in the translation of more research in this area. Methods: A web-search on PubMed, ScienceDirect, and Nature was performed with the keywords Customized 3D printing and Drug delivery, publications dealing with the aspects of drug delivery using 3D printing for personalized or customized delivery were further considered and analyzed and discussed. Results: We present the advantages offered by 3DP over conventional methods of formulation development and discuss the current state of 3DP in pharmaceutics and how it can be used to develop a truly customized drug delivery system, various 3DP technologies including Stereolithography (SLA), Selective Laser Sintering (SLS), Fused Deposition Modelling (FDM), Pressure Assisted Microsyringe (PAM) that have been used to develop pharmaceutical products have been discussed along with their limitations and also the regulatory considerations to help formulation scientists envisaging research in this area with the necessary information. Conclusion: 3D printing has the potential to fabricate a customized drug delivery system. Presence of many drug formulation and the devices are already in the regulatory approval process indicating its success.

1 January 2019 in Journal of Experimental Neuroscience
Verified
Journal Article
Open access
PDF file
PSPahul Preet Singh
Pahul Preet Singh
IGIshan Goel
Ishan Goel
AMAmit Kumar Mondal
Amit Kumar Mondal
FKFarooq Ali Khan
Farooq Ali Khan
ASAshish Kumar Singh
Ashish Kumar Singh
SKSukant Khurana
Sukant Khurana
Not much is known about disease prevalence, treatment outcomes, trained manpower, programs, and patients’ awareness of diseases from South Asia, compared with the Western world. While other aspects are improving, the quantitative evaluation of awareness of diseases is lagging. Compared with other diseases, the situation for mental health disorders and addiction is worse. While no single study can fully quantify all aspects of awareness, a good starting point is to understand if increasing the number of mental health facilities is beneficial by understanding people’s perception toward the likelihood of contracting various diseases, their preferred approach to treatment, and their perception of whether there are enough current facilities. We surveyed over 8000 families across several states of India and asked if they would treat a particular problem at home, visit a local healer, seek religious council, or go to a modern hospital for treatment. Our questions also included non-medical options to assess how likely people are to avoid trained medical help. We also asked people about their perceived likelihood of a family member ever suffering from (1) diarrhea, (2) high fever, (3) alcoholism, and (4) schizophrenia and other mental health problems. We reversed the order of diseases in our questions for a fraction of the population to evaluate the effect of order of questioning. Finally, we asked, if people feel they have enough local healers, religious places, general hospitals, de-addiction centers, and mental health facilities. Despite the taboo around mental health, many people claimed that their family members were unlikely to contract mental health or addiction problems, people recognized the severe paucity of mental health facilities and de-addiction centers. This raises hope for improving the mental health situation in India. We also found a significant relation between education levels and choices people make, underscoring the positive role education has in improving mental health.

1 January 2018 in Journal of Experimental Neuroscience
Verified
Journal Article
Open access
PDF file
Areeba PatelAreeba Patel
Areeba Patel
FKFarooq Ali Khan
Farooq Ali Khan
Arindam SikdarArindam Sikdar
Arindam Sikdar
AMAmit Kumar Mondal
Amit Kumar Mondal
SSSunil Dutt Shukla
Sunil Dutt Shukla
SKSukant Khurana
Sukant Khurana
Phytomedicine has often been used as “alternative therapy,” which in our opinion is unfortunate as it prevents its main actions being systematically studied, side effects explored, and toxicity tested, like all single-compound-based medicine. Our group is interested in finding which traditional or modern phytomedicines actually work and which are simply “working” through placebo, standardizing phytomedicine preparations, studying their toxicity, and finding active molecules in plants for modification and chemical synthesis as single compounds. Although fluctuation in efficacy due to seasonal and geographical variations in phytomedicine remains a concern, if well regulated, even plant extracts without isolated compounds can serve medicinal needs where single-compound options are currently not great. A potential concern with such phytomedicine is frequent mixing of ingredients in commercial formulations without test of synergism. Our study on the use of 2 traditional plants for Parkinson disease shows a clear lack of synergism, and to study nonsynergism better, we developed a new visualization approach. In this commentary, using our study on Parkinson disease as an example, we make a case for better evaluation of phytomedicines, especially testing for synergistic interactions. We also critique our own exploration of oxidative stress and few behavioral parameters alone to lay grounds for what we and hopefully others can do in future to extract more information from their phytomedicine studies. We hope this commentary acts as a good warning for anyone mixing 2 phytomedicines without testing.